Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.